Flavan-3-ols and Cardiometabolic Health: a Guideline Recommendation
There is a rapidly growing body of clinical data reflecting benefits of flavan-3-ol intake. Guideline recommendation for a plant bioactive such as flavan-3-ols is a departure from previous recommendations as it is not based on deficiencies but rather improvement in health outcomes. The objective to develop an intake recommendation for flavan-3-ols and cardiometabolic outcomes is to inform multiple stakeholders including clinicians, policymakers, public health entities, and consumers. 157 randomized controlled trials and 15 cohort studies were employed to develop the guideline. Moderate evidence supporting cardiometabolic protection resulting from flavan-3-ol intake in the range of 400-600 mg/d was supported in the literature. Increasing consumption of dietary flavan-3-ols may help improve blood pressure, cholesterol levels, and blood sugar. The new guideline is food-based and not a recommendation for flavan-3-ol supplements.
Crowe-White, Kristi M, Evans, Levi W, Kuhnle, Gunter G C, Milenkovic, Dragan, Stote, Kim, Wallace, Taylor, Handu, Deepa & Senkus, Katelyn E. 2022. Flavan-3-ols and Cardiometabolic Health: a Guideline Recommendation by the Academy of Nutrition and Dietetics. Advances in Nutrition doi: 10.1093/advances/nmac105.